Table 1.
Protection of GI JEV VLP vaccine against GI and GIII JEV infection in mice.
| Immunogens | JEV challenge (genotype) | FRμNT50 titers against JEV challenge | No. of surviving mice/total | Protective ratea (%) (surviving mice/total) | Average time to die (ATD) |
|---|---|---|---|---|---|
| GI VLP | YL2009-4 (I) | <10 | 0 | 100* (10/10) | — |
| 10–<40 | 1/1 | ||||
| 40–<160 | 6/6 | ||||
| ≥160 | 3/3 | ||||
| T1P1 (III) | <10 | 0 | 90* (9/10) | 9 | |
| 10–<40 | 2/2 | ||||
| 40–<160 | 5/6 | ||||
| ≥160 | 2/2 | ||||
| PBS | YL2009-4 (I) | <10 | 0/8 | 0 (0/8) | 9 |
| T1P1 (III) | <10 | 0/8 | 0 (0/8) | 8.5 |
aData was compared by Student t test. *P < 0.05.